tm
Seeing Is Believing
tm
Seeing Is Believing
Currently out of the existing stock ratings of Samantha Semenkow, 84 are a BUY (83.17%), 17 are a HOLD (16.83%).
Analyst Samantha Semenkow, currently employed at CITI, carries an average stock price target met ratio of 30.5% that have a potential upside of 27.83% achieved within 104 days. Previously, Samantha Semenkow worked at MONNESS CRESPI & HARDT.
Samantha Semenkow’s has documented 194 price targets and ratings displayed on 26 stocks. The coverage is on the Healthcare sector.
Most recent stock forecast was given on ROIV, Roivant Sciences Ltd at 10-Aug-2026.
Analyst best performing recommendations are on NGM (NGM BIOPHARMACEUTICALS).
The best stock recommendation documented was for NGM (NGM BIOPHARMACEUTICALS) at 2/27/2024. The price target of $1.55 was fulfilled within 1 day with a profit of $0.08 (4.91%) receiving and performance score of 49.08.
Average potential price target upside
Analyst name
Rating
Current price target
Potential Upside
Previous price target
Date of last PT
Price targets met ratio
Average potential upside
Average Days to Hit Target
Performance score
Hold Since 01-Dec-2022
$34
$0.91 (2.75%)
$31
Buy Since 05-Mar-2026
$52
$18.91 (57.15%)
$46
Buy Since 05-Jan-2024
$39
$5.91 (17.86%)
$41
Buy Since 24-Feb-2025
$55
$21.91 (66.21%)
$52
Buy Since 04-Dec-2021
$40
$2.1 (5.54%)
$41
Which stock is Samantha Semenkow is most bullish on?
Which stock is Samantha Semenkow is most reserved on?
What Year was the first public recommendation made by Samantha Semenkow?
